Patent safe harbor speeds generic drugs to patients, cuts litigation risk
S. 43 — Skinny Labels, Big Savings Act · Filed by John Hickenlooper (D-CO) · 3 cosponsors · Introduced Jan 9, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill creates a legal safe harbor allowing generic drug and biosimilar manufacturers to develop, seek approval for, and market drugs without infringing method-of-use patents—provided their labeling does not claim the patented use. In practice, it lets competitors sell drugs for unapproved uses while the original patent holder's exclusive use claims remain technically valid but unenforceable against the generic/biosimilar version.
Why we flagged it
The bill's operative mechanism is a narrow, conditional immunity from patent infringement liability for competitors who comply with labeling restrictions. It is not a blanket patent repeal but a targeted carve-out for a specific regulatory pathway (ANDA, 505(j), 351(k) applications).
What the text implies
- Patent holders retain legal title and can still sue if a competitor's labeling or promotion references the patented use—the safe harbor is conditional, not absolute, creating ongoing litigation risk over what constitutes a 'reference' to the patented condition.
- The bill applies retroactively to all pending proceedings, potentially reopening settled cases or dismissing ongoing patent suits against generic/biosimilar manufacturers.
The full analysis lists 4 implications of this text.
Who stands to gain
generic pharmaceutical manufacturers; biosimilar manufacturers; pharmacy benefit managers and insurers (lower drug costs)